Orexo Report Abstral (Rapinyl) Approval In Europe
Posted by in
Cancer on 06 30th, 2008 |
No Comments
Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the universal speciality...